The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog or Metformin Treatment
试验速览
- 阶段
- 4 期
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- physiological parameter:glycosylated hemoglobin A1c
研究概览
简要总结
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
详细描述
160 Type 2 diabetes in our hospital will divide into 4 groups: group A (40 healthy volunteers), group B (40 patients who give basal and insulin treatment, group C（40 patients who give basal and Liraglutide treatment),group D（40 patients who give basal and metformin treatment). The age, height, weight, blood glucose, glycosylated hemoglobin A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid, blood pressure, course of disease, telomere length,telomerase activity will record respectively. And High-sensitive C-reactive protein (HsCRP), Par-4, GST,SOD,GSH-PX,ATF-6,CHOP,XBP-1 and Tumor necrosis factor-α（TNF-α） will detect as Baseline. After each group's treatment, Change from baseline of all indexes will record, Multifactor logistic regression will be analyzed the correlations between each positive indexes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%;
- •Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);
排除标准
- •Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to insulin, islet cells, and GAD；
- •Gestational diabetes;
- •patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease;
研究组 & 干预措施
insulin
basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
干预措施: Liraglutide (Drug)
insulin
basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
干预措施: Metformin (Drug)
结局指标
主要结局
physiological parameter:glycosylated hemoglobin A1c
时间窗: up to 6 months;
up to 6 months;;HbA1c was measured by a certified hospital laboratory according to established and approved protocols
次要结局
- physiological parameter:the concentration of Par-4(up to 6 months;)
- physiological parameter:telomease activity(up to 6 months;)
- physiological parameter:TNF-α(up to 6 months;)
- physiological parameter:telomere length(up to 6 months;)
研究者
Wu Qinan
the Third Military Medical University
Third Military Medical University